Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
University of Miami
Headquarters: Coral Gables, FL, United States of America
Website: http://www.miami.edu
Year Founded: 1925
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Aug 3, 2024
Deals
Biotechs find problem-solving in academia, and mostly outside the big hubs
Academia-biotech deals span innovative assets to tissue bank resources to enabling technologies
BioCentury | Apr 17, 2024
Regulation
ODAC support for myeloma metric makes broader case for endpoint innovation
FDA advisory panel backs minimal residual disease as an accelerated approval endpoint for multiple myeloma
BioCentury | Nov 23, 2022
Data Byte
Translational spotlight on East-West innovation
Collaborations between investigators at Asian and Western universities in BioCentury’s Distillery present licensing and partnering opportunities
BioCentury | Jan 8, 2022
Product Development
Phagelux: new life in lysins
CEO Mark Engel narrows the focus of his cross-border biotech to first- and best-in-class skin products and phage-based platform technologies.
BioCentury | Oct 29, 2021
Emerging Company Profile
Walden: targeting podocytes as linchpin for kidney function
Backed by Arch and UCB, Walden to enter the clinic next year with a mAb and small molecule targeting podocytes for kidney diseases
BioCentury | Jul 30, 2021
Distillery Therapeutics
GHRH agonist to protect retinal ganglion cells from optic neuropathy
DISEASE CATEGORY: Ophthalmic
INDICATION: Optic neuropathy A team from the Chinese University of Hong Kong showed a GHRH receptor agonist could protect retinal ganglion cells from optic
INDICATION: Optic neuropathy A team from the Chinese University of Hong Kong showed a GHRH receptor agonist could protect retinal ganglion cells from optic
BioCentury | Oct 3, 2020
Emerging Company Profile
Emmecell: magnetic cell therapy for eye diseases
Emmecell is slated to begin Phase I testing in corneal edema patients next year
BioCentury | Mar 28, 2020
Product Development
COVID-19 crisis spurs innovation in rapid diagnostic technologies
A flood of new rapid diagnostic technologies is nearing the market to fight the COVID-19 pandemic
BioCentury | Jul 11, 2019
Distillery Therapeutics
SMPDL3b inhibition or C1P supplementation for diabetic kidney disease
Items per page:
1 - 10 of 165